Please use this identifier to cite or link to this item:
https://www.um.edu.mt/library/oar/handle/123456789/14835
Title: | Controlled trial with brinerdin : a new antihypertensive |
Authors: | Fenech, Frederick F. Soler, A.V. Vassallo Agius, Paul |
Keywords: | Antihypertensive agents -- Malta -- Case studies Hypotensive agents Hypertension -- Treatment Blood pressure |
Issue Date: | 1972 |
Publisher: | The St. Luke`s Hospital Gazette |
Citation: | Fenech, F.F., Soler, A., & Vassallo Agius, P. (1972). Controlled trial with brinerdin : a new antihypertensive. The St. Luke`s Hospital Gazette, 7(1), 38-41. |
Abstract: | A double-blind study on 40 ambulant, mild to moderate hypertensive patients aged from 35-67 years is presented. After a dose-adjustment period and a 3-week wash-out the patients were randomized into 2 groups each on active drug and placebo respectively. Regular physical and laboratory examinations were made. The Brinerdin group showed a highly significant fall in blood pressure. In all cases the fall was gradual without sudden fluctuation. By comparison the placebo group showed only insignificant changes in blood pressure. At the effective dosage of 1-3 tablets daily there were no untoward side-effects. As with all saluretic drugs some patients tended to have slightly raised uric acid levels. The study demonstrates that at a dosage of 1-3 tablets per day Brinerdin is an effective anti-hypertensive agent. In all cases comparison with placebo showed a highly significant difference in favour of Brinerdin. |
URI: | https://www.um.edu.mt/library/oar//handle/123456789/14835 |
Appears in Collections: | TSLHG, Volume 7, Issue 1 TSLHG, Volume 7, Issue 1 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Controlled Trial with Brinerdin.pdf | Published for the Consultant Staff Committee, St. Luke`s Hospital, Malta and the Medical and Dental Surgery Faculties of the Royal University of Malta. | 233.94 kB | Adobe PDF | View/Open |
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.